Boston Scientific Joins U.S. Climate Action Partnership
Group supports call for limiting greenhouse gas emissions

NATICK, Mass., May 18 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has joined the U.S. Climate Action Partnership (USCAP). USCAP was formed as a non-partisan alliance of major businesses and leading climate and environmental groups that have come together to promote legislation that would require significant reductions of greenhouse gas (GHG) emissions.

"Boston Scientific is proud to join USCAP to address the serious issue of climate change," said Boston Scientific Chairman of the Board and Co-Founder Pete Nicholas. "As a company, Boston Scientific will continue to introduce practices to reduce its own environmental impact while helping promote legislative solutions that benefit the environment while creating economic opportunities that support the U.S. economy."

USCAP is asking lawmakers to enact an economy-wide policy that covers all major GHG-emitting sectors. The cornerstone of this approach would be a cap on GHG emissions and a trade program and associated policies across the economy to limit atmospheric GHG concentrations in an effort to minimize large-scale impacts to humans and the environment. The group recommends that Congress adopt a solution that would establish short- and mid-term GHG emission reduction targets; a national program to accelerate technology research, development and deployment; and approaches to encourage action by other countries, including those in the developing world.

USCAP has produced a set of principles and recommendations entitled "A Call for Action" to guide the formation of a regulated economy-wide, market- driven approach to climate protection. USCAP's goal is to slow, stop and ultimately reverse the growth of greenhouse gas emissions over the shortest period of time reasonably achievable.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, operating effectiveness and efficiencies, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

  CONTACT:  Paul Donovan
            508-650-8541 (office)
            508-667-5165 (mobile)
            Media Relations
            Boston Scientific Corporation

            Dan Brennan
            508-650-8538 (office)
            617-459-2703 (mobile)
            Investor Relations
            Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Paul Donovan, Media Relations, +1-508-650-8541 (office),
+1-508-667-5165 (mobile), or Dan Brennan, Investor Relations, +1-508-650-8538
(office), +1-617-459-2703 (mobile), both of Boston Scientific Corporation

Web site: